Brief: Timber Pharmaceuticals Announces 50% Enrollment In Phase 2B Control Study In Congenital Ichthyosis

Trex Wind-Down

15/03/2021 13:12

March 15 (Reuters) - Timber Pharmaceuticals Inc  TMBR.A :
    * TIMBER PHARMACEUTICALS ANNOUNCES 50% ENROLLMENT IN PHASE
2B
CONTROL STUDY IN CONGENITAL ICHTHYOSIS
    * TIMBER PHARMACEUTICALS INC - STUDY IS EVALUATING TMB-001
(TOPICAL ISOTRETINOIN) IN SUBTYPES OF RARE GENETIC
KERATINIZATION DISORDER
    * TIMBER PHARMACEUTICALS INC - AWARDED FINAL TRANCHE OF $1.5
MILLION FDA ORPHAN PRODUCTS CLINICAL TRIALS GRANT
    * TIMBER PHARMACEUTICALS INC - PHASE 2B CONTROL STUDY IS
TARGETING
ENROLLMENT OF 45 PATIENTS AGED NINE YEARS OLD AND OLDER

Source text for Eikon:  ID:nGNX6qHtWm 
Further company coverage:  TMBR.A 

 ((Reuters.Briefs@thomsonreuters.com;))